Tezepelumab and severe asthma

TEZEPELUMAB AND SEVERE ASTHMA: TOWARD A REDUCTION IN ORAL STEROIDS?

In recent years, the management of severe asthma has undergone a profound transformation thanks to the introduction of biologic therapies. Among these, tezepelumab—a monoclonal antibody that acts upstream of the inflammatory cascade—is attracting particular interest.

Recent clinical data suggest that this drug could enable a significant reduction in the chronic use of oral corticosteroids, one of the main goals in the management of patients with severe asthma.

The issue of steroids in severe asthma

Oral corticosteroids remain a cornerstone of treatment for patients with uncontrolled severe asthma. However, their chronic use is associated with numerous side effects, including:

· osteoporosis

· diabetes

· hypertension

· infections

· metabolic changes

For this reason, the scientific community has identified as a priority the possibility of reducing or eliminating the use of systemic steroids while maintaining disease control.

Tezepelumab: an innovative mechanism of action

Tezepelumab is a monoclonal antibody directed against thymic stromal lymphopoietin (TSLP), an epithelial cytokine involved in the early stages of the inflammatory response.

Unlike other biologics, which act on more specific pathways (such as IL-5 or IL-4/IL-13), tezepelumab:

· acts upstream of the inflammatory cascade

· modulates various immunological pathways

· is effective regardless of eosinophil levels.

This makes it potentially useful in a broader population of patients with severe asthma.

Clinical trial results

Recent data from randomized clinical trials have evaluated the effect of tezepelumab in patients with severe asthma receiving oral corticosteroids.

The main results show that:

· over 50% of treated patients were able to completely discontinue oral steroids

· a significant reduction in dosage was observed in the remaining patients

· asthma control was maintained or improved

· improvements in respiratory function and quality of life were recorded.

These data have been reported in international clinical studies and presented at conferences and in scientific publications, with reference to controlled trials published and discussed in recent literature (e.g., studies on tezepelumab published in journals such as the New England Journal of Medicine and Lancet Respiratory Medicine).

Clinical Implications

The ability to reduce or eliminate steroids is a fundamental goal in the management of severe asthma.

The introduction of tezepelumab could enable:

· reduction of systemic side effects

· improvement in quality of life

· greater personalization of therapy

· more effective management of patients unresponsive to other biologics.

Furthermore, its mechanism of action makes it particularly promising for patients with:

· non-eosinophilic asthma

· mixed or complex phenotypes

· limited response to other biologics.

A paradigm shift in pulmonology

The introduction of tezepelumab reflects a broader shift in respiratory medicine:

· from symptom control → to modulation of the disease’s biological mechanisms

· from “one-size-fits-all” therapy → to personalized medicine

· from chronic steroid use → to steroid-sparing strategies

This represents one of the most significant advances in recent years in the management of severe asthma.

Limitations and future prospects

Despite promising results, some questions remain:

· identifying patients who respond best

· economic sustainability of biologic therapies

· direct comparison with other biologics

· long-term safety data.

Further studies will be needed to define the optimal role of tezepelumab in different asthma phenotypes.

The possibility of drastically reducing the use of corticosteroids is one of the main goals of modern pulmonology. Tezepelumab stands out for its upstream mechanism of action, which makes it potentially effective in a broader population compared to other biologics.

If confirmed in the long term, these results could mark the end of chronic steroid use in many patients with severe asthma.

Tezepelumab represents one of the most significant innovations in the treatment of severe asthma.

Its ability to reduce or eliminate the use of corticosteroids opens new avenues for safer and more effective disease management.

Pulmonology is entering a phase where therapy is no longer merely symptomatic, but increasingly targeted, biologic, and personalized.